In vivo evidence that secretion of HLA‐G by immunogenic tumor cells allows their evasion from immunosurveillance

International Journal of Cancer - Tập 135 Số 9 - Trang 2107-2117 - 2014
Laure Loumagne1,2, Jérémy Baudhuin1,2, Benoı̂t Favier1,2, Florent Montespan1,2, Edgardo D. Carosella1,2, Nathalie Rouas‐Freiss1,2
1CEA, IMETI, Service de Recherches en Hemato-Immunologie (SRHI), Hopital Saint-Louis, Paris, France
2Institut Universitaire d'Hematologie (IUH), Hopital Saint-Louis, UMR_E5, Universite Paris-Diderot-Paris-7, Paris, France

Tóm tắt

Human leukocyte antigen‐G (HLA‐G) expression by tumors has been evidenced in numerous malignancies in association with poor prognosis and resistance to immunotherapy in humans. Particularly, soluble form of HLA‐G was measured at high concentrations in malignant effusions and plasma from cancer patients, and inhibits antitumor immune cells in vitro through interaction with immunoglobulin‐like transcript (ILT) receptors. Nevertheless, in vivo study demonstrating that HLA‐G secretion by tumor cells allows their escape from immunosurveillance remained to be established. Despite nondescribed murine homolog, direct functional interaction of HLA‐G with murine paired immunoglobulin‐like receptor (PIR)‐B, ortholog of human ILT receptors, enables to investigate its role in vivo. Immunocompetent mice were injected either with syngeneic tumor cells co‐expressing HLA‐G5, the main soluble HLA‐G isoform, and the conformation stabilizer human β2‐microglubulin (hβ2m), or with hβ2m+HLA‐G5− tumor cells. hβ2m expressed at both tumor cell surface acted as a tumor antigen triggering a specific humoral response. Interestingly, although hβ2m+HLA‐G5− tumors were rejected, secreted HLA‐G5 provided hβ2m+HLA‐G5+ tumors a protection against hβ2m‐elicited immune rejection, enabling such immunogenic tumors to grow similarly to a poorly immunogenic tumor. HLA‐G5 tumor expression was associated with local and peripheral immunosuppression, characterized by dampened anti‐hβ2m B‐cell response, quantitative and functional T‐and B‐cell defects, accumulation of myeloid‐derived suppressor cells able to inhibit T‐cell proliferation and reduced T‐ and B‐cell tumor infiltrate. Our study provides the first in vivo proof that soluble HLA‐G counteracts tumor rejection and reinforces the importance to consider HLA‐G as a promising target to optimize current cancer immunotherapies.

Từ khóa


Tài liệu tham khảo

10.1038/nri1961

10.1038/nri1936

10.1016/j.it.2007.11.005

10.1002/ijc.21151

10.1002/ijc.10460

10.1093/intimm/9.5.645

10.2174/187153011794982059

10.1002/eji.201141761

Singer G, 2003, HLA‐G is a potential tumor marker in malignant ascites, Clin Cancer Res, 9, 4460

10.1016/j.humimm.2009.07.019

10.4049/jimmunol.176.3.1331

10.4049/jimmunol.176.5.3266

10.1007/s00018-011-0632-7

10.1002/eji.200736918

10.1002/eji.200425741

10.1038/leu.2012.62

10.4049/jimmunol.1300438

10.1158/0008-5472.CAN-06-4588

10.1111/j.1365-2141.2007.06647.x

10.1002/1521-4141(200209)32:9<2418::AID-IMMU2418>3.0.CO;2-L

10.1155/2011/275302

10.1016/j.humimm.2003.08.348

10.1093/intimm/13.3.385

10.1182/blood-2010-07-294389

10.1016/j.humimm.2012.11.021

10.1002/ijc.26375

10.1038/nri2506

10.1002/eji.1830250621

10.1002/ijc.27755

10.1111/j.1365-2613.2007.00539.x

10.4049/jimmunol.181.8.5791

10.1182/blood-2010-11-321752

10.1007/s00281-012-0344-6

10.1038/nm.2537

10.4161/onci.22428

10.1158/0008-5472.CAN-05-0097

10.4049/jimmunol.1001323

10.1189/jlb.0604337

10.1016/j.immuni.2011.02.004

10.1038/ni1074

10.4049/jimmunol.0803277

10.1182/blood-2004-03-0859

10.1038/nri3175

10.1182/blood-2009-07-234872

10.1111/j.1349-7006.2011.01951.x

10.1111/j.1365-2249.2012.04657.x

10.1007/s00262-011-1028-0

10.1189/jlb.0111021

10.1002/ijc.25807

Thông tin
Thông tin xuất bản

International Journal of Cancer

Tập 135 Số 9

2107-2117

Thông tin tác giả